Biocon 公司获得英国首个利拉鲁肽仿制药批准，标志着减肥药仿制药利润丰厚供应的开始。 Biocon secures UK's first approval for generic liraglutide, marking the start of a lucrative generic supply for weight loss meds.
随着畅销药物专利到期，印度生物科技公司 Biocon Ltd. 正将重点转向抗肥胖疗法，到 2030 年仿制药市场规模将达到 1000 亿美元。 Biocon Ltd., an Indian biotech firm, is shifting focus to anti-obesity therapies as patents for blockbuster medications expire, fueling a $100 billion generic drug market by 2030. Biocon 公司获得了英国首个批准的利拉鲁肽注射剂仿制药，该药物用于减肥，并于 11 月失去专利保护。 Biocon secured the UK's first approval for a generic version of liraglutide injectable, used in weight loss and losing patent protection in November. 这标志着利润丰厚的减肥药仿制药供应浪潮的开始。 This marks the beginning of a lucrative wave of generic supply for weight loss medications.